Date: 2012-12-16
Type of information: Company acquisition
Acquired company: AbD Serotec, MorphoSys's Research and Diagnostic Antibody Business (Germany)
Acquiring company: Bio-Rad (USA)
Amount: € 53 million
Terms: MorphoSys has agreed to sell its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, a multinational manufacturer and distributor of life science research and clinical diagnostic products. The total consideration amounts to approximately € 53 million and will be settled in cash. The total consideration comprises the purchase price, compensation for cash reserves in the AbD Serotec companies in the amount of approximately € 5 million and a license payment for the use of the HuCAL technology in the research and diagnostic markets.
The transaction is subject to certain closing conditions, and is expected to be completed in January, 2013.
According to the terms of the transaction, Bio-Rad Laboratories will acquire all of MorphoSys's AbD Serotec research reagent and diagnostic business, comprising the AbD Serotec segment of MorphoSys AG as well as the subsidiaries MorphoSys UK Ltd., MorphoSys AbD GmbH and MorphoSys US, Inc. In addition, the transaction includes a fully paid-up, non-exclusive license agreement to use MorphoSys's HuCAL technology for diagnostic and research purposes.
* On January 10, 2013, MorphoSys has announced that the sale of its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories has been completed. All assets and liabilities of the AbD Serotec segment of MorphoSys AG as well as all shares of the subsidiaries MorphoSys UK Ltd., MorphoSys AbD GmbH and MorphoSys US, Inc. have been transferred to Bio-Rad.
Details:
Related: diagnostic
